期刊
JOURNAL OF INFECTIOUS DISEASES
卷 217, 期 12, 页码 1907-1917出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiy102
关键词
HCMV; vaccine; humoral responses; AD2; glycoprotein B
资金
- European Union under the FP7 Marie Curie Action VacTrain [316655]
- Deutsche Forschungsgemeinschaft [MA 929/11-1]
- Medical Research Council Fellowship [G:0900466]
- National Institute of Allergy and Infectious Diseases [R01AI051355]
- Pasteur
- MRC [G0900466] Funding Source: UKRI
The human cytomegalovirus (HCMV) virion envelope protein glycoprotein B (gB) is essential for viral entry and represents a major target for humoral responses following infection. Previously, a phase 2 placebo-controlled clinical trial conducted in solid organ transplant candidates demonstrated that vaccination with gB plus MF59 adjuvant significantly increased gB enzyme-linked immunosorbent assay (ELISA) antibody levels whose titer correlated directly with protection against posttransplant viremia. The aim of the current study was to investigate in more detail this protective humoral response in vaccinated seropositive transplant recipients. We focused on 4 key antigenic domains (AD) of gB (AD1, AD2, AD4, and AD5), measuring antibody levels in patient sera and correlating these with posttransplant HCMV viremia. Vaccination of seropositive patients significantly boosted preexisting antibody levels against the immunodominant region AD1 as well as against AD2, AD4, and AD5. A decreased incidence of viremia correlated with higher antibody levels against AD2 but not with antibody levels against the other 3 ADs. Overall, these data support the hypothesis that antibodies against AD2 are a major component of the immune protection of seropositives seen following vaccination with gB/MF59 vaccine and identify a correlate of protective immunity in allograft patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据